Accordingly, both technologies reported the overexpression of STIM1, MBP, SEPTIN9, and SEPTIN10 and the downregulation of CRACR2A, ORMDL3, SARAF, SEPTIN3, and SEPTIN6 in colon cancer cells. This evidence concerns the gene MBP and malignant colon neoplasm.